LMO2 induces T-cell leukemia with epigenetic deregulation of CD4

Experimental Hematology

Volumn 42, Issue 7, 2014, Pages 581-593.e5

  Cleveland, Susan M ^a   Goodings, Charnise ^a   Tripathi, Rati M ^a   Elliott, Natalina ^a   Thompson, Mary Ann ^a   Guo, Yan ^a   Shyr, Yu ^a   Davé, Utpal P ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DEXAMETHASONE; HISTONE DEACETYLASE; MESSENGER RNA; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR RUNX1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CD4 GENE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; LIM DOMAIN ONLY 2 ONCOGENE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; T CELL LEUKEMIA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD4; EPIGENESIS, GENETIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, T-CELL; LIM DOMAIN PROTEINS; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS;

EID: 84904898579     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.04.010     Document Type: Article

References (58)

1. Deichmann A., Hacein-Bey-Abina S., Schmidt M., et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007, 117:2225-2232.
2. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
3. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
4. Dave U.P., Akagi K., Tripathi R., et al. Murine leukemias with retroviral insertions at LMO2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet 2009, 5:e1000491.
5. Dave U.P., Jenkins N.A., Copeland N.G. Gene therapy insertional mutagenesis insights. Science 2004, 303:333.
6. Matthews J.M., Lester K., Joseph S., et al. LIM-domain-only proteins in cancer. Nat Rev Cancer 2013, 13:111-122.
7. Warren A.J., Colledge W.H., Carlton M.B., et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994, 78:45-57.
8. Yamada Y., Warren A.J., Dobson C., et al. The T cell leukemia LIM protein LMO2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci U S A 1998, 95:3890-3895.
9. McCormack M.P., Forster A., Drynan L., et al. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol Cell Biol 2003, 23:9003-9013.
10. Tsai F.Y., Keller G., Kuo F.C., et al. An early haematopoietic defect inmice lacking the transcription factor GATA-2. Nature 1994, 371:221-226.
11. Shivdasani R.A., Mayer E.L., Orkin S.H. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCK. Nature 1995, 373:432-434.
12. Schlaeger T.M., Mikkola H., Gekas C., Helgadottir H.B., Orkin S.H. Tie2Cre-mediated gene ablation defines the stem-cell leukemia gene (SCL/tal1)-dependent window during hematopoietic stem-cell development. Blood 2005, 105:3871-3874.
13. Li L., Freudenberg J., Cui K., et al. Ldb1-nucleated transcription complexes function as primary mediators of global erythroid gene activation. Blood 2013, 121:4575-4585.
14. Li L., Lee J.Y., Gross J., et al. A requirement for Lim domain binding protein 1 in erythropoiesis. J Exp Med 2010, 207:2543-2550.
15. McCormack M.P., Young L.F., Vasudevan S., et al. The LMO2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 2010, 327:879-883.
16. Cleveland S.M., Smith S., Tripathi R., et al. LMO2 induces hematopoietic stem cell-like features in T-cell progenitor cells before leukemia. Stem Cells 2013, 31:882-894.
17. Ceredig R., Rolink T. A positive look at double-negative thymocytes. Nat Rev Immunol 2002, 2:888-897.
18. Bhandoola A., Sambandam A. From stem cell to T cell: one route or many?. Nat Rev Immunol 2006, 6:117-126.
19. Herblot S., Steff A.-M., Hugo P., et al. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-Talpha. chain expression. Nat Immunol 2000, 1:138-144.
20. Mingueneau M., Kreslavsky T., Gray D., et al. The transcriptional landscape of alphabeta T cell differentiation. Nat Immunol 2013, 14:619-632.
21. Drynan L.F., Hamilton T.L., Rabbitts T.H. T cell tumorigenesis in LMO2 transgenic mice is independent of V-D-J recombinase activity. Oncogene 2001, 20:4412-4415.
22. Treanor L.M., Volanakis E.J., Zhou S., et al. Functional interactions between LMO2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood 2011, 117:5453-5462.
23. Tatarek J., Cullion K., Ashworth T., et al. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/LMO2 mouse model of T-ALL. Blood 2011, 118:1579-1590.
24. Clappier E., Gerby B., Sigaux F., et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011, 208:653-661.
25. Chiu P.P., Jiang H., Dick J.E. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood 2010, 116:5268-5279.
26. Shackleton M., Quintana E., Fearon E.R., et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
27. Smith S.B., Tripathi R., Goodings C., et al. LIM domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways. PLoS ONE 2014, 9:e85883.
28. Wildt K.F., Sun G., Grueter B., et al. The transcription factor Zbtb7b promotes CD4 expression by antagonizing Runx-mediated activation of the CD4 silencer. J Immunol 2007, 179:4405-4414.
29. Smith S., Tripathi R., Goodings C., et al. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways. PLoS ONE 2014, 9:e85883.
30. Grigliatti T. Position-effect variegation-an assay for nonhistone chromosomal proteins and chromatin assembly and modifying factors. Methods Cell Biol 1991, 35:587-627.
31. Taniuchi I., Osato M., Egawa T., et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during Tlymphocyte development. Cell 2002, 111:621-633.
32. Taniuchi I., Ellmeier W., Littman D.R. The CD4/CD8 lineage choice: new insights into epigenetic regulation during T cell development. Adv Immunol 2004, 83:55-89.
33. Gialitakis M., Sellars M., Littman D.R. The epigenetic landscape of lineage choice: lessons from the heritability of CD4 and CD8 expression. Curr Top Microbiol Immunol 2012, 356:165-188.
34. Jiang H., Peterlin B.M. Differential chromatin looping regulates CD4expression in immature thymocytes. Mol Cell Biol 2008, 28. 907-907.
35. Yu M., Wan M., Zhang J., Wu J., Khatri R., Chi T. Nucleoprotein structure of the CD4 locus: Implications for the mechanisms underlying CD4 regulation during T cell development. Proc Natl Acad Sci US A 2008, 105:3873-3878.
36. Girton J.R., Johansen K.M. Chromatin structure and the regulation of gene expression: the lessons of PEV in Drosophila. Adv Genet 2008, 61:1-43.
37. Chi T.H., Wan M., Zhao K., et al. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. Nature 2002, 418:195-199.
38. Taniuchi I., Sunshine M.J., Festenstein R., et al. Evidence for distinct CD4 silencer functions at different stages of thymocyte differentiation. Mol Cell 2002, 10:1083-1096.
39. Williams C.J., Naito T., Arco P.G., et al. The chromatin remodeler Mi-2beta is required for CD4 expression and T cell development. Immunity 2004, 20:719-733.
40. Reed-Inderbitzin E., Moreno-Miralles I., Vanden-Eynden S.K., et al. RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene 2006, 25:5777-5786.
41. Collins A., Littman D.R., Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol 2009, 9:106-115.
42. Egawa T., Littman D.R. Transcription factor AP4 modulates reversible and epigenetic silencing of the Cd4 gene. Proc Natl Acad Sci U S A 2011, 108:14873-14878.
43. Chong M.M., Simpson N., Ciofani M., Chen G., Collins A., Littman D.R. Epigenetic propagation of CD4 expression is established by the Cd4 proximal enhancer in helper T cells. Genes Dev 2010, 24:659-669.
44. Xiong J., Armato M.A., Yankee T.M. Immature single-positive CD8+ thymocytes represent the transition from Notch-dependent to Notch-independent T-cell development. Int Immunol 2011, 23:55-64.
45. Fiorini E., Merck E., Wilson A., et al. Dynamic regulation of notch 1 and notch 2 surface expression during T cell development and activation revealed by novel monoclonal antibodies. J Immunol 2009, 183:7212-7222.
46. Huang E.Y., Gallegos A.M., Richards S.M., et al. Surface expression of Notch1 on thymocytes: correlation with the double-negative to double-positive transition. J Immunol 2003, 171:2296-2304.
47. Naito T., Gómez-Del Arco P., Williams C.J., Georgopoulos K. Antagonistic interactions between Ikaros and the chromatin remodeler Mi-2beta determine silencer activity and Cd4 gene expression. Immunity 2007, 27:723-734.
48. Lutterbach B., Westendorf J.J., Linggi B., et al. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 2000, 275:651-656.
49. Aronson B.D., Fisher A.L., Blechman K., et al. Groucho-dependent and -independent repression activities of Runt domain proteins. Mol Cell Biol 1997, 17:5581-5587.
50. Telfer J.C., Hedblom E.E., Anderson M.K., et al. Localization of the domains in Runx transcription factors required for the repression of CD4 in thymocytes. J Immunol 2004, 172:4359-4370.
51. Sanda T., Lawton L.N., Barrasa M.I., et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 2012, 22:209-221.
52. Zhang J., Ding L., Holmfeldt L., et al. The genetic basis of early T-cellprecursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
53. van Riel B., Pakozdi T., Brouwer R., et al. A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells. Mol Cell Biol 2012, 32:3814-3822.
54. Meier N., Krpic S., Rodriguez P., et al. Novel binding partners of Ldb1 are required for haematopoietic development. Development 2006, 133:4913-4923.
55. Jiang H., Zhang F., Kurosu T., et al. Runx1 binds positive transcription elongation factor b and represses transcriptional elongation by RNA polymerase II: possible mechanism of CD4 silencing. Mol Cell Biol 2005, 25:10675-10683.
56. Bai X., Kim J., Yang Z., et al. TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell 2010, 142:133-143.
57. Kong F.K., Chen C.L., Cooper M.D. Reversible disruption of thymic function by steroid treatment. J Immunol 2002, 168:6500-6505.
58. Screpanti I., Morrone S., Meco D., et al. Steroid sensitivity of thymocyte subpopulations during intrathymic differentiation. Effects of 17 beta-estradiol and dexamethasone on subsets expressing T cell antigen receptor or IL-2 receptor. J Immunol 1989, 142:3378-3383.